Quantification of viral loads lower than 50 copies per milliliter by use of the cobas ampliprep/cobas taqman HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter

Journal of Clinical Microbiology

Volumn 51, Issue 5, 2013, Pages 1555-1557

  Estévez, Marta Alvarez ^a   Porcuna, Natalia Chueca ^a   Suay, Vicente Guillot ^a   Monge, Alejandro Peña ^a   García, Fernando García ^a   Medina, Leopoldo Muñoz ^a   García, David Vinuesa ^a   Ruiz, Jorge Parra ^a   Hernández Quero, Jose ^a   García, Federico García ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DEVICE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REBOUND; RETROSPECTIVE STUDY; VIRUS LOAD; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; RECURRENT DISEASE; VIREMIA; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84876771770     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00100-13     Document Type: Article

References (14)

1. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, Kelley CF, Hunt PW, Hoh R, Linnen JM, Martin JN, Busch MP, Deeks SG. 2010. Evidence of persistent low-level viremia in long-term HAARTsuppressed, HIV-infected individuals. AIDS 24:2535-2539.
2. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
3. Manavi K. 2008. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin. Trials 9:283-286.
4. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbò A, Angeletti C, Capobianchi MR. 2011. Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J. Clin. Virol. 52:17-22.
5. Church D, Gregson D, Lloyd T, Klein M, Beckthold B, Laupland K, Gill MJ. 2011. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q. v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J. Clin. Microbiol. 49:118-124.
6. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, Trabaud MA, Tardy JC, Morand P, Pozzetto B, Ecochard R, André P. 2011. HIV-1 load comparison using four commercial real-time assays. J. Clin. Microbiol. 49:292-297.
7. Alvarez M, Chueca N, Guillot V, del Carmen Bernal M, García F. 2012. Improving clinical laboratory efficiency: introduction of systems for the diagnosis and monitoring of HIV infection. Open Virol. J. 6:135-143.
8. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 54:724-732.
9. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J. Acquir. Immune Defic. Syndr. 60:473-482.
10. Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P. 2012. Persistent lowlevel HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome. J. Antimicrob. Chemother. 67:2231-2235.
11. Boillat-Blanco N, Darling KEA, Schöni-Affolter F, Rougemont M, Fulchini R, Bernasconi E, Vuichard D, Aouri M, Clerc O, Furrer H, Günthard HF, Cavassini M. 2012. Persistent low-level viraemia in HIV-1-infected patients: Swiss HIV Cohort Study, abstr H-1566. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
12. Henrich TJ, Wood BR, Kuritzkes DR. 2012. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load-48 copies/mL. PLoS One 7:e50065. doi:10.1371/journal.pone.0050065.
13. Van Rensburg EJ, Tait K, Watt A, Schall R. 2011. Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 assay. J. Clin. Microbiol. 49:377-379.
14. Parra-Ruiz J, Alvarez M, Chueca N, Peña A, Pasquau J, López-Ruz MA, Maroto MDC, Hernández-Quero J, García F. 2009. Genotypic resistance in HIV-1-infected patients with persistent low-level viremia. (In Spanish.) Enferm. Infecc. Microbiol. Clin. 27:75-80.